GIP/GLP1 CO-AGONIST COMPOUNDS

The present invention relates to compounds having activity at both the human glucose- dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The present invention also relates to compounds having an extended duration of action at each of these receptors. Furthermor...

Full description

Saved in:
Bibliographic Details
Main Authors WALLIS, James Lincoln, ABURUB, Aktham, SLOOP, Kyle Wynn, BROWN, Robert Andrew, ELSAYED, Mohamed ElSayed Hamed, ABRAHAM, Milata Mary, TRAN, Thi Thanh Huyen, PATEL, Phenil Jayantilal, QU, Hongchang, WILLARD, Francis Stafford, CUMMINS, Robert Chadwick, CABRERA, Over, DATTA-MANNAN, Amita, ALSINA-FERNANDEZ, Jorge, LAI, Xianyin, COSKUN, Tamer
Format Patent
LanguageEnglish
Published 25.06.2023
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present invention relates to compounds having activity at both the human glucose- dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The present invention also relates to compounds having an extended duration of action at each of these receptors. Furthermore, the present invention relates to compounds that may be administered orally. Compounds may be useful in the treatment of type 2 diabetes mellitus (?T2DM?). Also, the compounds may be useful in the treatment of obesity.
Bibliography:Application Number: MY2021PI00294